vs
OneMain Holdings, Inc.（OMF）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
OneMain Holdings, Inc.的季度营收约是Revvity的1.4倍（$1.1B vs $772.1M），OneMain Holdings, Inc.净利率更高（18.7% vs 12.7%，领先5.9%），OneMain Holdings, Inc.同比增速更快（8.3% vs 5.9%），过去两年OneMain Holdings, Inc.的营收复合增速更高（10.4% vs 9.0%）
OneMain Holdings, Inc.是一家美国金融服务控股企业，总部位于印第安纳州埃文斯维尔，在全美多地设有核心办事机构。公司全资持有OneMain金融公司及其子公司，以OneMain Financial为品牌经营消费金融与保险业务，主要面向难以从银行等传统贷款机构获得服务的客户提供个人贷款及可选保险产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
OMF vs RVTY — 直观对比
营收规模更大
OMF
是对方的1.4倍
$772.1M
营收增速更快
OMF
高出2.5%
5.9%
净利率更高
OMF
高出5.9%
12.7%
两年增速更快
OMF
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $204.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 22.8% | 14.5% |
| 净利率 | 18.7% | 12.7% |
| 营收同比 | 8.3% | 5.9% |
| 净利润同比 | 61.9% | 3.9% |
| 每股收益（稀释后） | $1.71 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OMFRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $996.0M | $664.8M | ||
| Q4 24 | $1.0B | $729.4M | ||
| Q3 24 | $981.0M | $684.0M | ||
| Q2 24 | $922.0M | $691.7M | ||
| Q1 24 | $896.0M | $649.9M |
净利润OMFRVTY
| Q4 25 | $204.0M | $98.4M | ||
| Q3 25 | $199.0M | $46.7M | ||
| Q2 25 | $167.0M | $53.9M | ||
| Q1 25 | $213.0M | $42.2M | ||
| Q4 24 | $126.0M | $94.6M | ||
| Q3 24 | $157.0M | $94.4M | ||
| Q2 24 | $71.0M | $55.4M | ||
| Q1 24 | $155.0M | $26.0M |
毛利率OMFRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率OMFRVTY
| Q4 25 | 22.8% | 14.5% | ||
| Q3 25 | 24.5% | 11.7% | ||
| Q2 25 | 20.9% | 12.6% | ||
| Q1 25 | 27.6% | 10.9% | ||
| Q4 24 | 16.3% | 16.3% | ||
| Q3 24 | 21.1% | 14.3% | ||
| Q2 24 | 10.0% | 12.4% | ||
| Q1 24 | 22.8% | 6.8% |
净利率OMFRVTY
| Q4 25 | 18.7% | 12.7% | ||
| Q3 25 | 18.6% | 6.7% | ||
| Q2 25 | 16.3% | 7.5% | ||
| Q1 25 | 21.4% | 6.4% | ||
| Q4 24 | 12.5% | 13.0% | ||
| Q3 24 | 16.0% | 13.8% | ||
| Q2 24 | 7.7% | 8.0% | ||
| Q1 24 | 17.3% | 4.0% |
每股收益（稀释后）OMFRVTY
| Q4 25 | $1.71 | $0.86 | ||
| Q3 25 | $1.67 | $0.40 | ||
| Q2 25 | $1.40 | $0.46 | ||
| Q1 25 | $1.78 | $0.35 | ||
| Q4 24 | $1.05 | $0.77 | ||
| Q3 24 | $1.31 | $0.77 | ||
| Q2 24 | $0.59 | $0.45 | ||
| Q1 24 | $1.29 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $914.0M | $919.9M |
| 总债务越低越好 | $22.7B | — |
| 股东权益账面价值 | $3.4B | $7.3B |
| 总资产 | $27.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 6.67× | — |
8季度趋势，按日历期对齐
现金及短期投资OMFRVTY
| Q4 25 | $914.0M | $919.9M | ||
| Q3 25 | $658.0M | $931.4M | ||
| Q2 25 | $769.0M | $991.8M | ||
| Q1 25 | $627.0M | $1.1B | ||
| Q4 24 | $458.0M | $1.2B | ||
| Q3 24 | $577.0M | $1.2B | ||
| Q2 24 | $667.0M | $2.0B | ||
| Q1 24 | $831.0M | $1.7B |
总债务OMFRVTY
| Q4 25 | $22.7B | — | ||
| Q3 25 | $22.3B | — | ||
| Q2 25 | $22.1B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.4B | — | ||
| Q3 24 | $21.1B | — | ||
| Q2 24 | $20.7B | — | ||
| Q1 24 | $19.5B | — |
股东权益OMFRVTY
| Q4 25 | $3.4B | $7.3B | ||
| Q3 25 | $3.4B | $7.4B | ||
| Q2 25 | $3.3B | $7.6B | ||
| Q1 25 | $3.3B | $7.6B | ||
| Q4 24 | $3.2B | $7.7B | ||
| Q3 24 | $3.2B | $7.9B | ||
| Q2 24 | $3.2B | $7.9B | ||
| Q1 24 | $3.2B | $7.8B |
总资产OMFRVTY
| Q4 25 | $27.4B | $12.2B | ||
| Q3 25 | $27.0B | $12.1B | ||
| Q2 25 | $26.6B | $12.4B | ||
| Q1 25 | $26.0B | $12.4B | ||
| Q4 24 | $25.9B | $12.4B | ||
| Q3 24 | $25.6B | $12.8B | ||
| Q2 24 | $25.1B | $13.4B | ||
| Q1 24 | $23.9B | $13.4B |
负债/权益比OMFRVTY
| Q4 25 | 6.67× | — | ||
| Q3 25 | 6.61× | — | ||
| Q2 25 | 6.63× | — | ||
| Q1 25 | 6.55× | — | ||
| Q4 24 | 6.72× | — | ||
| Q3 24 | 6.59× | — | ||
| Q2 24 | 6.56× | — | ||
| Q1 24 | 6.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $865.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | 4.24× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流OMFRVTY
| Q4 25 | $865.0M | $182.0M | ||
| Q3 25 | $828.0M | $138.5M | ||
| Q2 25 | $774.0M | $134.3M | ||
| Q1 25 | $665.0M | $128.2M | ||
| Q4 24 | $752.0M | $174.2M | ||
| Q3 24 | $677.0M | $147.9M | ||
| Q2 24 | $712.0M | $158.6M | ||
| Q1 24 | $558.0M | $147.6M |
自由现金流OMFRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率OMFRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度OMFRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率OMFRVTY
| Q4 25 | 4.24× | 1.85× | ||
| Q3 25 | 4.16× | 2.97× | ||
| Q2 25 | 4.63× | 2.49× | ||
| Q1 25 | 3.12× | 3.03× | ||
| Q4 24 | 5.97× | 1.84× | ||
| Q3 24 | 4.31× | 1.57× | ||
| Q2 24 | 10.03× | 2.87× | ||
| Q1 24 | 3.60× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OMF
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
